#1 Clinical Trials Search in Europe

Mosliciguat

A groundbreaking clinical trial is underway to assess the effectiveness and safety of Mosliciguat, an innovative inhaled medication for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). This Phase 2 study aims to provide new hope for those suffering from this complex condition by exploring the potential benefits of this novel treatment approach.

Table of Contents

What is Mosliciguat?

Mosliciguat is a new medication currently being studied for its potential to treat a specific type of lung and heart condition. It’s important to note that this drug is still in the research phase and is not yet approved for general use[1].

What Conditions Does Mosliciguat Target?

Mosliciguat is being developed to treat a condition called pulmonary hypertension associated with interstitial lung disease (PH-ILD). Let’s break down what this means:

  • Pulmonary Hypertension (PH): This is high blood pressure in the arteries of the lungs. It can make it harder for the heart to pump blood through the lungs, which can lead to shortness of breath and fatigue.
  • Interstitial Lung Disease (ILD): This refers to a group of disorders that cause scarring (fibrosis) of the lungs. This scarring can make it difficult to breathe and get oxygen to the bloodstream.

When these two conditions occur together, it’s called PH-ILD. This combination can be particularly challenging for patients, affecting both their heart and lung function[1].

How is Mosliciguat Administered?

Mosliciguat is designed to be inhaled, which means patients breathe it directly into their lungs. It’s administered using a special device called a dry powder inhaler. This method of delivery is intended to target the medication directly to the lungs where it’s needed most[1].

Current Clinical Trial

Mosliciguat is currently being studied in a Phase 2 clinical trial. Here are some key points about this study:

  • It’s a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to either receive Mosliciguat or a placebo (a substance with no active medication), and neither the participants nor the researchers know who is receiving which until the study is complete.
  • The study lasts for 24 weeks, followed by an extension period.
  • During the first 24 weeks, some participants will receive Mosliciguat while others receive a placebo.
  • After 24 weeks, all participants may have the opportunity to receive Mosliciguat in the extension period[1].

Expected Benefits of Mosliciguat

While the full benefits of Mosliciguat are still being studied, researchers are hoping to see improvements in several areas:

  1. Reduced Pulmonary Vascular Resistance (PVR): This could mean that blood flows more easily through the lungs, potentially making breathing easier.
  2. Improved Exercise Capacity: Researchers will measure how far patients can walk in 6 minutes to see if the medication helps improve physical endurance.
  3. Better Heart Function: By measuring levels of a substance called NT-proBNP in the blood, researchers can assess if the medication is helping to reduce strain on the heart[1].

How the Study Measures Effectiveness

The researchers will use several methods to determine if Mosliciguat is working:

  • Right Heart Catheterization: This procedure measures the pressure in the heart and lungs directly. It will be used to assess changes in pulmonary vascular resistance (PVR).
  • Six-Minute Walk Test (6MWT): This simple test measures how far a person can walk in 6 minutes. It’s a good way to assess overall exercise capacity and endurance.
  • Blood Tests: Specifically, they’ll measure levels of NT-proBNP, a substance that can indicate how hard the heart is working[1].

It’s important to remember that Mosliciguat is still in the research phase. While the results of this study are not yet known, they will help determine if this medication could be a valuable treatment option for people with PH-ILD in the future.

Aspect Details
Study Type Phase 2, randomized, double-blind, placebo-controlled
Drug Mosliciguat (inhaled)
Condition Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
Duration 24-week double-blind period + extension period
Primary Outcome Change in Pulmonary Vascular Resistance (PVR) from Baseline to Week 16
Secondary Outcomes Change in Six-Minute Walk Test (6MWT) distance and NT-proBNP levels
Administration Dry Powder Inhaler

FAQ

  • What is Mosliciguat and how is it administered? Mosliciguat is a new drug being tested for pulmonary hypertension associated with interstitial lung disease. It is administered through inhalation using a dry powder inhaler, making it easy for patients to use at home.
  • What is the main goal of this clinical trial? The main goal is to evaluate the safety and effectiveness of inhaled Mosliciguat in patients with PH-ILD. The study will measure changes in pulmonary vascular resistance and other important factors to determine if the drug improves the condition.
  • How long does the clinical trial last? The trial consists of a 24-week double-blind period where participants receive either Mosliciguat or a placebo. After this, there is an extension period where all participants may receive Mosliciguat.
  • What are some of the key measurements used in the trial? The trial measures several important factors, including pulmonary vascular resistance (PVR), distance achieved in the Six-Minute Walk Test (6MWT), and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the blood.
  • Who can participate in this clinical trial? While specific eligibility criteria are not provided, the trial is designed for patients diagnosed with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Interested individuals should consult with their healthcare providers about potential participation.

Ongoing Clinical Trials on Mosliciguat

  • Study on the Effects of Mosliciguat for Patients with Pulmonary Hypertension Linked to Interstitial Lung Disease

    Not recruiting

    1
    Investigated drugs:
    Belgium Czechia France Germany Italy Latvia +3

Glossary

  • Pulmonary Hypertension (PH): A condition characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure.
  • Interstitial Lung Disease (ILD): A group of disorders that cause scarring (fibrosis) of lung tissue, making it difficult to breathe and get enough oxygen into the bloodstream.
  • PH-ILD: Pulmonary Hypertension associated with Interstitial Lung Disease, a complex condition where both PH and ILD are present.
  • Mosliciguat: An investigational drug being studied for the treatment of PH-ILD, administered through inhalation.
  • Dry Powder Inhaler: A device used to deliver medication directly to the lungs in the form of a dry powder.
  • Pulmonary Vascular Resistance (PVR): A measure of the resistance that must be overcome to push blood through the circulatory system in the lungs.
  • Right Heart Catheterization (RHC): A procedure used to evaluate heart function and measure pressures in the heart and lungs.
  • Six-Minute Walk Test (6MWT): A test that measures the distance a person can walk quickly on a flat surface in 6 minutes, used to assess exercise capacity.
  • N-terminal pro-brain natriuretic peptide (NT-proBNP): A substance in the blood that can indicate the severity of heart failure.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment or placebo.
  • Randomized: A method of assigning participants to different treatment groups by chance, to reduce bias in the study results.

References